Abstract
Twenty-five patients with systemic malignancies or cutaneous disorders were treated with low dosages (1-16 IU/kg/day) of oral interferon-α in a phase-I study. There were no grade-3 or -4 toxicities. No patient achieved a partial or complete response. One patient with renal cell carcinoma had prolonged disease stabilization lasting for 22 months. No significant changes in lymphocyte subsets including T4/T8 ratio, or serum immunoglobulins were observed. Subjective improvement in general well-being was reported by three patients. Low dosages of interferon-α administered orally do not appear to have any significant immunomodulatory or antitumor activity.
Original language | English (US) |
---|---|
Pages (from-to) | 51-55 |
Number of pages | 5 |
Journal | Journal of Immunotherapy |
Volume | 14 |
Issue number | 1 |
State | Published - 1993 |
Keywords
- Interferon-α
- Oral administration
- Phase I
- Systemic effect
ASJC Scopus subject areas
- Immunology
- Pharmacology
- Cancer Research